StreetAlpha.app
Home › Stocks › SPRO

Spero Therapeutics, Inc. (SPRO)

Healthcare
$0.74
▼ −10.20%
LAST CLOSE · NOV 20

Spero Therapeutics develops tebipenem HBr, an oral antibiotic in development for complicated urinary tract infections in adults. It last closed at $0.74 on Nov 20, down 10.20% on the day. The next earnings report for SPRO is expected around Thu, Mar 25, 2027, after the close. For the quarter ended Sep 2026, SPRO reported EPS of -$0.76 on revenue of $0, with revenue down 100.0% from a year ago. Over its last 8 reports the stock moved an average of 6.9% the session after earnings. Over the last 12 months SPRO insiders bought $0 of stock on the open market and sold $499K, according to SEC Form 4 filings.

AI Auto Pilots
Is SPRO in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold SPRO.

Key Stats

Last 12 months
Results
Revenue
$41.6M
+2.5% vs a year ago
Net income
−$29.5M
−71.0% margin
EPS (diluted)
−$0.50
Operating margin
−67.3%
−$28.0M operating income
Valuation
Market cap
$43.2M
58.3M shares
P/E
–
No P/E while losing money
Price to sales
1.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$107.9M
At Sep 30
Shareholder equity
$781K
Shares outstanding
58.3M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $18.3M$18.3MFY2021FY2022: $53.5M$53.5MFY2022FY2023: $103.8M$103.8MFY2023FY2024: $48.0M$48.0MFY2024FY2025: $66.8M$66.8MFY2025

From SPRO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
Mar 25
Estimated date · After the close
Reported EPS
-$0.76
Quarter ended Sep 2026
Year ago EPS
-$0.13
Same quarter last year
Revenue
$0
−100.0% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.38Dec '24Mar 2025: -$0.25Mar '25Jun 2025: -$0.03Jun '25Sep 2025: -$0.13Sep '25Dec 2025: $0.56Dec '25Mar 2026: -$0.13Mar '26Jun 2026: -$0.16Jun '26Sep 2026: -$0.76Sep '26Latest -$0.76
Revenue by quarter
Dec 2024: $15.0MDec '24Mar 2025: $5.9MMar '25Jun 2025: $14.2MJun '25Sep 2025: $5.4MSep '25Dec 2025: $41.3MDec '25Mar 2026: $258,000Mar '26Jun 2026: $0Jun '26Sep 2026: $0Sep '26Latest $0
How SPRO moved after its last 8 reports
Average move the session after a report ±6.9%
Nov 12, 2026After the close−0.0%
Aug 12, 2026After the close+4.2%
May 13, 2026After the close+13.1%
Mar 26, 2026After the close−1.7%
Nov 13, 2025After the close−1.2%
Aug 12, 2025After the close−18.0%
May 13, 2025After the close−5.8%
Mar 27, 2025After the close−10.9%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on SPROStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on SPRO
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on SPRO

Technical Analysis

SPRO · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 36% below its 20 day and 49% below its 50 day average. It is 154% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 23), oversold. The nearest support is the 52 week low at $0.73, and the nearest resistance the Pivot at $0.76.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 9.8%/day
Key levels
$3.0852 week high+316.2%
$1.88200 day average+154.1%
$1.24100 day average+67.6%
$1.18Swing high (Oct 28)+59.5%
$1.1150 day average+50.0%
$1.0120 day average+36.5%
$0.79Pivot R1+6.8%
$0.76Pivot+2.7%
$0.74Last close
$0.7352 week low−1.4%
$0.71Pivot S1−4.1%
Indicators
RSI (14)22.58Oversold below 30Oversold
MACD-0.08Below its signal lineBearish
Stochastic3.5Near the bottom of its rangeOversold
ADX (14)24.0Weak trend
Williams %R-96.7Oversold below −80, overbought above −20Oversold
CCI (20)-234.1Oversold below −100, overbought above 100Oversold
Rate of change−28.0%Change over 10 sessionsBearish
ATR (14)$0.07Typical daily range, 9.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for SPRO

What happened before

See how SPRO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow SPRO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How SPRO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for SPROHow many large options trades hit SPRO, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

SPRO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲36 buying vs 28 selling
  • ▲Held by funds +7.5 pts
  • ▲Funds holding +1
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding6261+1.6%
In funds' top 1012−50.0%
Held by funds44.5%36.9%+7.5 pts
New / increased19 / 1722 / 17−7.7%
Reduced / sold out11 / 176 / 12+55.6%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SPRO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

SPRO Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$499K6 sales · 2 insiders
2026-02 sold $393K2026-05 sold $63K2026-11 sold $42KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 9Esther RajaveluSee RemarksSale40,851$1.04$42K
May 4Esther RajaveluSee RemarksSale25,240$2.51$63K
Feb 6Timothy KeutzerCOOSale18,652$2.36$44K
Feb 6Esther RajaveluSee RemarksSale87,917$2.36$207K
Feb 4Timothy KeutzerCOOSale46,586$2.17$101K
Feb 2Esther RajaveluSee RemarksSale18,442$2.20$41K
Every insider buy and sale for SPRO over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See SPRO insider trades →

From SEC Form 4 filings by SPRO's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SPRO is in one of them and how their past SPRO trades turned out.

SPRO in the AI portfolios
Loading…

SPRO News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SPRO in an article yet. Here's the latest on the wider market.

SPRO in the news

About Spero Therapeutics

Spero Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, that develops treatments for rare diseases and diseases with high unmet need. Its main product candidate is tebipenem HBr, an oral tablet antibiotic in development to treat complicated urinary tract infections in adults with limited oral treatment options. The company has no products approved for sale, and GSK is developing and commercializing tebipenem HBr under a license agreement. Its intended users are adult patients and the physicians who treat them.

Headquarters
Cambridge, MA